

RECEIVED
CENTRAL FAX CENTER

MAR 01 2006

PATENT

Practitioner's Docket No. 2003DE108

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Heckmann et al.

Application No.: 10/550,995

Group No.:

Filed: September 26, 2005

For: Heterocyclic Dyes Based on Benzodipyrroles

Commissioner for Patent

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

CERTIFICATION UNDER 37 C.F.R. Sections 1.8(a) and 1.10*
*(When using Express Mail, the Express Mail label number is mandatory;
 Express Mail certification is optional.)*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

☐ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. section 1.8(a)

37 C.F.R. section 1.10*

☐ with sufficient postage as first class mail.

☐ as "Express Mail Post Office to Address"
 Mailing Label No. _____ (mandatory)

TRANSMISSION

☒ transmitted by facsimile to the Patent and Trademark Office (571) 273-8300.

Date: March 1, 2006

Signature

Jackie L. Wise

(type or print name of person certifying)

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b).
 "Since the filing of correspondence under [section] 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Applicant: Heckmann et al.
Serial No. 10/550,995
Page 2

Dear Sir:

In accordance with the duty of disclosure provisions of 37 CFR §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the subject application. No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor a representation that a search has been made (other than search report(s) from a counterpart foreign application or a PCT International Search Report, if submitted herewith).


1. ☒ Enclosures accompanying this Information Disclosure Statement are:
 - 1a. ☒ Form PTO-1449.
 - 1b. ☒ Copies of Information Disclosure Statement citations:
 - 1c. ☐ PCT Search Report
 - 1d. ☐ Copies of Co-pending U.S. Applications.
2. ☐ This Information Disclosure Statement is filed under 37 CFR §1.97(b) with the filing of the U.S. patent application. Accordingly, no fee or §1.97(e) Statement is required.
3. ☒ This Information Disclosure Statement is filed under 37 CFR §1.97(b) before the latter of three months after the U.S. patent application filing date or the first Office Action on the merits. Accordingly, no fee or §1.97(e) Statement is required.
4. ☐ This Information Disclosure Statement is filed under 37 CFR §1.97(c) after the first Office Action on the merits, but before a Final Office Action or a Notice of Allowance. The \$180.00 fee set forth in 37 CFR §1.17(p) in accordance with 37 CFR §1.97(c) is to be charged to Deposit Account No. 03-2060.
5. ☐ This Information Disclosure Statement is filed under 37 CFR §1.97(e) in that each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Accordingly, no fee is required.
6. ☐ This Information Disclosure Statement is filed in conjunction with a Request For Continued Examination. Accordingly, no fee or §1.97(e) Statement is required.

Applicant: Heckmann et al.
Serial No. 10/550,995

Page 3

7. ☒ The English language documents identified by reference in the TRANSLATION Section of the foreign patents list of the attached 1449 Form are believed to be a concise statement, or the equivalent or substantial equivalent to the foreign language documents cited in the attached 1449 Form.
8. ☐ In addition to the documents cited, the Office's attention is directed to the following co-pending U.S. Application Serial Number(s), copies of which are attached for the convenience of the Office:
- a.
b.
c.
9. ☒ The document entitled "Angnew. Chemie 99 (10)", pp. 1068-1070, cited herein, describes salt like compounds comprising the dianion of 2,2',2'',2''' benzo [1,2-c:5-c'] dipyrrole-1,3,5,7,(2H,6H)-tetraylidene tetrakispropane-dinitrile.

Respectfully submitted,



Anthony A. Bisulca
Registration No. 40,913

CUSTOMER NO. 25,255

Clariant Corporation
Industrial Property Department
4000 Monroe Road
Charlotte, North Carolina 28205
Telephone: 704/331-7151
Facsimile: 704/331-7707

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (37 CFR 1.98(b))	ATTY. DOCKET NO. 2003DE108	SERIAL NO. 10/550,995
	APPLICANT: Heckmann et al.	
	FILING DATE: 9/26/2005	GROUP:

U.S. PATENT DOCUMENTS

Examiner Initial		Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date if Appropriate
	AA	4,122,087	10/24/1978	Greenhalgh et al.			
	AB	5,021,573	6/4/1991	Bitterli et al.			
	AC						
	AD						
	AE						
	AF						
	AG						
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION							
		DOCUMENT NUMBER	PUB. DATE	COUNTRY			TRANSLATION
	BA	DE 3911643	11/2/1989	Germany			See AB above
	BB	DE 2236629	2/8/1973	Germany			English Abstract
	BC						
	BD						
	BE						
	BF						
	BG						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication**)

	CA	PCT International Search Report for PCT/EP 2004/0001799, mailed 7/14/2004
	CB	Closs et al., "2,6-Diaza-s-indcenes," Angewandte Chemie International Edition, England, Vol. 10, pp 1037-1039, XP 002282814, (1987)
	CC	Angew. Chem. 99(10), pp. 1060-1070 (1987).
EXAMINER		DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		